Insights
57 results found
The Association of the British Pharmaceutical Industry (ABPI) has issued a policy proposal aimed at supporting the delivery of the NHS 10-Year Plan.
13 May 2025The plan is built around three core shifts in care: from hospital to community, from analogue to digital, and from treatment to prevention. These shifts reference the government’s ambition to deliver economic growth through improved health outcomes.
NICE introduces promising improvements to the routing criteria for highly specialised technologies designed to treat rare diseases
13 May 2025The newly approved routing criteria is hoped to clearly define the circumstances for when highly specialised technologies (HSTs) will be routed to the HST programme which is designed to evaluate technologies for ultra-rare debilitating conditions.
ABPI and UK Government bring forward VPAG pricing review
01 May 2025The UK Government and the Association of the British Pharmaceutical Industry (ABPI) have agreed to accelerate the planned review of the Voluntary Scheme for Branded Medicines Pricing, Access and Growth (VPAG).Sustainability - why this is now crucial for pharma business leaders?
01 Apr 2025Whether your business is in early stage drug discovery and R&D or manufacturing, supply, and distribution, every part of the pharma ecosystem is now under increasing pressure to adopt sustainable practices.Spending on medicines and medical devices increases but VPAG clawback reach record levels
01 Apr 2025NHS spending on medicines, appliances and medical devices in England hit £19.9bn in 2023/24, with £14.6bn in branded medicine sales. However, the VPAG clawback is meanwhile expected to be an unprecedented £3.5bn in 2025, £1bn more than previously forecastNHS England abolished - what does this mean for pharma?
01 Apr 2025This is not about abolishing the NHS, but a plan to redirect money from bureaucracy to frontline treatments of patients.
